Adeno virus vector manufacturing platform using CIMmultus QA column to produce safer vaccines cheaper
Adenovirus has after two decades gained new consideration and is now used as a COVID-19 vaccine delivery vehicle. To reduce side effects of the vaccine it’s purity is of utmost importance. Constant enhancement of the vaccine purity and improvement of the impurity detection methods is therefore necessitated. In this work we present second generation adenoviral vectors purification procedure based on monolith chromatography using CIMmultus QA to secure safer product, as well the accompanying analytical tools. The novel industrial process secures better purity at higher yields. The robustness of the process was verified using different upstream materials. Manufacturing of the vaccines in large quantities due to pandemic represent great challenges, mainly in terms of production time and costs. Higher capacity of the CIMmultus QA columns used in this process overcomes the raw material supply bottlenecks.